---
schema_version: "secwatch.filing_event.v1"
accession: "0001824293-25-000094"
form_type: "8-K"
ticker: "GRI"
cik: "0001824293"
company_name: "GRI Bio, Inc."
filed_at: "2025-07-31T23:59:59+00:00"
generated_at: "2026-05-17T22:26:51.103331+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# GRI Bio reports positive interim biomarker data from Phase 2a IPF study; IDMC recommends continuation

## Summary
- 6-week interim data from Phase 2a study of GRI-0621 in IPF show reduced fibrogenesis and increased fibrolysis in treated patients.
- IDMC recommended study continue as planned; no safety concerns seen to date.
- Phase 2a study fully enrolled; topline data expected Q3 2025.
- GRI-0621 patients demonstrated increased basement membrane remodeling and potential repair mechanism vs control.
- Additional pulmonary function test results expected in coming weeks; flow cytometry and gene expression data later.

## SEC filing metadata
- accession: 0001824293-25-000094
- form_type: 8-K
- ticker: GRI
- cik: 0001824293
- company_name: GRI Bio, Inc.
- filed_at: 2025-07-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824293/000182429325000094/0001824293-25-000094-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824293/000182429325000094/val-20250731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001824293-25-000094
- JSON: https://secwatch.observer/filing/0001824293-25-000094.json
- Plain text: https://secwatch.observer/filing/0001824293-25-000094.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.